EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Real-World Safety of Vedolizumab in Inflammatory Bowel Disease: A Retrospective Cohort Study Supported by FAERS Signal Analysis

Bojana Milašinović, Sandra Vezmar Kovačević iD, Srđan Marković iD, Marija Jovanović iD, Tamara Knežević Ivanovski, Đorđe Kralj iD, Petar Svorcan iD, Branislava Miljković iD, Katarina Vučićević iD

Pharmaceuticals · 28.07.2025 · 18 (8) · 1127

DOI: 10.3390/ph18081127 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Pharmaceuticals, online erschienen am 28.07.2025. Verfasst von Bojana Milašinović und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacokinetics and Clinical Pharmacy, Faculty of Pharmacy, University of Belgrade, 11000 Belgrade, Serbia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science Fund of the Republic of Serbia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Vedolizumab is a gut-selective anti-integrin monoclonal antibody approved for the treatment of inflammatory bowel disease (IBD). While clinical trials have demonstrated a favorable safety profile, real-world studies are essential for identifying rare adverse events (AEs) and evaluating post-marketing safety. This study assessed vedolizumab’s safety in a real-world cohort and supported the detection of potential safety signals.

Methods

A retrospective chart review was conducted on adult IBD patients treated with vedolizumab at a tertiary center in the Republic of Serbia between October 2021 and August 2022. Data included demographics, AEs, and newly reported extraintestinal manifestations (EIMs). Exposure-adjusted incidence rates were calculated per 100 patient-years (PYs). Disproportionality analysis using the FDA Adverse Event Reporting System (FAERS) was performed to identify safety signals, employing reporting odds ratios (RORs) and proportional reporting ratios (PRRs) for AEs also observed in the cohort. Prior IBD therapies and reasons for discontinuation were evaluated.

Results

A total of 107 patients (42.1% Crohn’s disease, 57.9% ulcerative colitis) were included, with a median vedolizumab exposure of 605 days. There were 92 AEs (56.51/100 PYs), most frequently infections (23.95/100 PYs), gastrointestinal disorders (4.30/100 PYs), and skin disorders (4.30/100 PYs). The most frequently reported preferred terms (PTs) included COVID-19, COVID-19 pneumonia, nephrolithiasis, and nasopharyngitis. Arthralgia (12.90/100 PYs) was the most frequent newly reported EIM. No discontinuations due to vedolizumab AEs occurred. FAERS analysis revealed potential signals for events not listed in prescribing information but observed in the cohort: nephrolithiasis, abdominal pain, diarrhea, malaise, cholangitis, gastrointestinal infection, blood pressure decreased, weight decreased, female genital tract fistula, respiratory symptom, and appendicectomy. Most patients had received three prior therapies, often stopping one due to AEs.

Conclusions

Vedolizumab demonstrated a favorable safety profile in the IBD cohort. However, FAERS-identified signals, such as nephrolithiasis, gastrointestinal infections, and decreased blood pressure, warrant further investigation in larger, more diverse populations.

Schlagwörter

Stichwörter der Autor:innen

IBDexposure-adjusted incidence ratesmonoclonal antibodysafetysafety signalsvedolizumab

Autor:innen und Institutionen

  • Department of Pharmacokinetics and Clinical Pharmacy, Faculty of Pharmacy, University of Belgrade, 11000 Belgrade, Serbia.
  • Department of Gastroenterology and Hepatology, University Hospital Medical Center "Zvezdara", 11000 Belgrade, Serbia.
  • Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.

ORCID-Profile: Sandra Vezmar Kovačević, Srđan Marković, Marija Jovanović, Đorđe Kralj, Petar Svorcan, Branislava Miljković, Katarina Vučićević

Förderung

  • Science Fund of the Republic of Serbia

Zitieren

APA

Milašinović, B., Vezmar Kovačević, S., Marković, S., Jovanović, M., Knežević Ivanovski, T., Kralj, Đ., Svorcan, P., Miljković, B., & Vučićević, K. (2025). Real-World Safety of Vedolizumab in Inflammatory Bowel Disease: A Retrospective Cohort Study Supported by FAERS Signal Analysis. Pharmaceuticals, 18(8), 1127. https://doi.org/10.3390/ph18081127

Vancouver

Milašinović B, Vezmar Kovačević S, Marković S, Jovanović M, Knežević Ivanovski T, Kralj Đ, et al. Real-World Safety of Vedolizumab in Inflammatory Bowel Disease: A Retrospective Cohort Study Supported by FAERS Signal Analysis. Pharmaceuticals. 2025;18(8):1127. doi:10.3390/ph18081127

BibTeX
@article{Milainovi2025,
  author = {Milašinović, Bojana and Vezmar Kovačević, Sandra and Marković, Srđan and Jovanović, Marija and Knežević Ivanovski, Tamara and Kralj, Đorđe and Svorcan, Petar and Miljković, Branislava and Vučićević, Katarina},
  title = {Real-World Safety of Vedolizumab in Inflammatory Bowel Disease: A Retrospective Cohort Study Supported by FAERS Signal Analysis},
  journal = {Pharmaceuticals},
  year = {2025},
  volume = {18},
  number = {8},
  pages = {1127},
  doi = {10.3390/ph18081127}
}
Kostenlos starten →